ライフサイエンスコーパス: epoetin

1 tment with recombinant human erythropoietin (epoetin).

2 herapy received filgrastim and 6.8% received epoetin.

3 igher in the comparison of peginesatide with epoetin.

4 matologic response before considering use of epoetin.

5 matologic response before considering use of epoetin.

6 tions, hyperphosphatemia, beta-blockers, and epoetin.

7 ment with either subcutaneous or intravenous epoetin.

8 alysis treatment and intravenous maintenance epoetin.

9 gy (ASCO/ASH) recommendations for the use of epoetin.

10 ered, on average, an additional 3306 U/wk of epoetin.

11 versus 60,600 dollars and 64,311 dollars for epoetin.

12 ge for patients who continued treatment with epoetin (-0.75 g/L, -2.26 to 0.75) (p<0.0001 for both co

13 SP was threefold longer than for intravenous Epoetin (25.3 versus 8.5 h), a difference of 16.8 h (95%

14 ume of distribution was similar for NESP and Epoetin (52.4 +/- 2.0 ml/kg versus 48.7 +/-2.1 ml/kg; me

15 dialysis facility ownership and the dose of epoetin administered.

16 e, administered monthly, was as effective as epoetin, administered one to three times per week, in ma

17 Among 34 patients who received epoetin after the onset of PRCA, 56% regained epoetin re

18 design, the single-dose pharmacokinetics of Epoetin alfa (100 U/kg) and an equivalent peptide mass o

19 eekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 addition

20 io, to either GM-CSF (0.3-5.0 microg/kg.d) + epoetin alfa (150 IU/kg 3 times/wk) or GM-CSF (0.3-5.0 m

21 ed to receive luspatercept (178 patients) or epoetin alfa (178 patients), comprising 198 (56%) men an

22 g luspatercept (42 weeks [IQR 20-73]) versus epoetin alfa (27 weeks [19-55]).

23 Epoetin alfa (40,000 U) or placebo was administered week

24 sly (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120

25 be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56

26 United States with darbepoetin alfa (DA) or epoetin alfa (EA).

27 ninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat

28 Epoetin alfa (EPO) robustly induced bone marrow erythrof

29 showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression

30 Patients received epoetin alfa 10,000 U three times weekly, which could be

31 tarting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n =

32 Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be

33 Patients received epoetin alfa 40,000 U once weekly, which could be increa

34 enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by e

35 After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be admini

36 ts who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neoreco

37 erall tumor response was similar between the epoetin alfa and placebo groups after three chemotherapy

38 Epoetin alfa and placebo groups had similar median overa

39 Epoetin alfa and placebo patients (n = 109 and n = 115,

40 ; P=0.67) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume

41 Percentages of patients in the epoetin alfa and the placebo groups requiring transfusio

42 s transfused during the 12-week study in the epoetin alfa and the placebo groups were 5.9 and 9.5, re

43 Concordantly, epoetin alfa appeared to increase hemoglobin levels and

44 Epoetin alfa appears to have a beneficial impact on pati

45 These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related

46 multiple times and pooling preservative-free epoetin alfa caused this outbreak of bloodstream infecti

47 This study assessed whether epoetin alfa could maintain RBV dose, improve quality of

48 The pharmacokinetics of epoetin alfa did not predict pharmacodynamic response in

49 t that in newly diagnosed patients with SCLC epoetin alfa does not affect tumor response to chemother

50 The use of epoetin alfa does not reduce the incidence of red-cell t

51 The results suggest that epoetin alfa effectively improves functional outcomes in

52 ight, subcutaneously, once every 3 weeks) or epoetin alfa for at least 24 weeks.

53 fied interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-r

54 showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stim

55 were punctured multiple times, and residual epoetin alfa from multiple vials was pooled and administ

56 the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV

57 ell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo gr

58 red in 4 of 45 (9%) patients in the GM-CSF + epoetin alfa group compared with 1 of 21 (5%) patients w

59 pt group and 48 (31%) of 154 patients in the epoetin alfa group reached the primary endpoint (common

60 oncentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0

61 e interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3%

62 red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% conf

63 147 in the luspatercept group and 154 in the epoetin alfa group) who completed 24 weeks of treatment

64 pt group and 20.3 months (12.7-30.9) for the epoetin alfa group.

65 pt group and 16.9 months (10.1-26.6) for the epoetin alfa group.

66 nd headache; and none (>=3% patients) in the epoetin alfa group.

67 GM-CSF +/- epoetin alfa had no effect on mean platelet count.

68 ving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compar

69 Prescription of epoetin alfa has been associated with increased survival

70 erature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to referen

71 HIF-PHI (daprodustat) or an injectable ESA (epoetin alfa if they were receiving hemodialysis or darb

72 ased haemoglobin were achieved compared with epoetin alfa in ESA-naive patients with lower-risk myelo

73 ective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia

74 ted in patients who switched from placebo to epoetin alfa in the OLP.

75 inical trials have shown that treatment with epoetin alfa increases hemoglobin levels, reduces fatigu

76 Treatment with epoetin alfa is associated with an increase in the incid

77 Epoetin alfa is effective in improving the functional st

78 Epoetin alfa maintained RBV dose and improved QOL and Hb

79 s or reactions were associated with doses of epoetin alfa of more than 4000 U (multivariate odds rati

80 To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted i

81 olled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic

82 led trial (N93-004) evaluated the effects of epoetin alfa on tumor response to chemotherapy and survi

83 domly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered wit

84 In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in an

85 Fewer epoetin alfa patients than placebo patients required tra

86 s maintained in the prechemotherapy range in epoetin alfa patients, but decreased substantially in pl

87 roxadustat three times weekly or parenteral epoetin alfa per local clinic practice.

88 ajority of these patients received Eprex, an epoetin alfa product marketed exclusively outside the Un

89 In conclusion, epoetin alfa provided clinically significant HRQL improv

90 lodysplastic syndromes (six [3%]); and among epoetin alfa recipients (n=179) were anaemia (14 [8%]),

91 ine [5%] luspatercept recipients and 13 [7%] epoetin alfa recipients) and COVID-19 (eight [4%] luspat

92 ht [4%] luspatercept recipients and ten [6%] epoetin alfa recipients).

93 One of six dosing epoetin alfa regimens for 15 days, as follows: 40,000 IU

94 inical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well a

95 Treatment with epoetin alfa resulted in significant increases in hemogl

96 Epoetin alfa safely and effectively ameliorates anemia a

97 Epoetin alfa significantly improved HgB and reduced tran

98 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-w

99 were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 1

100 were associated with higher median doses of epoetin alfa than the 188 other sessions (6500 vs. 4000

101 ted from pooled epoetin alfa, empty vials of epoetin alfa that had been pooled, antibacterial soap, a

102 As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in eit

103 and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are sim

104 mmunity-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decrea

105 the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases i

106 Epoetin alfa therapy was also associated with a signific

107 Epoetin alfa therapy was associated with improved qualit

108 30, 1,047 patients completed all 4 months of epoetin alfa therapy.

109 The administration of the ESA epoetin alfa to critically ill trauma patients has been

110 Administration of epoetin alfa to older adult patients with heart failure

111 Addition of epoetin alfa to radical radiotherapy did not affect surv

112 he authors aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients i

113 ized, double-blind clinical trial evaluating epoetin alfa versus placebo in anemic cancer patients.

114 igue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.

115 were maintained in 88% of patients receiving epoetin alfa vs. 60% of patients receiving placebo (P <

116 Epoetin alfa was administered subcutaneously once a week

117 In addition, epoetin alfa was associated with a significant increase

118 As compared with placebo, epoetin alfa was associated with a significant increase

119 Epoetin alfa was associated with significant increases i

120 After the practice of pooling epoetin alfa was discontinued and the contaminated soap

121 Once-weekly epoetin alfa was well tolerated, with most adverse event

122 Epoetin alfa was well tolerated.

123 Epoetin alfa was well tolerated; the most common adverse

124 odysplastic syndromes, and syncope; and with epoetin alfa were anaemia, pneumonia, neutropenia, hyper

125 that preservative-free, single-use vials of epoetin alfa were punctured multiple times, and residual

126 Patients receiving epoetin alfa who had the greatest Hb increases from rand

127 or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarc

128 sized that treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricula

129 Mean Hb increased by 2.2 +/- 1.3 g/dL (epoetin alfa) and by 0.1 +/- 1.0 g/dL (placebo) in the D

130 safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct E

131 mulating factor (GM-CSF) and erythropoietin (epoetin alfa) in anemic, neutropenic patients with myelo

132 Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia

133 erapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfu

134 ers of Eprex, Epogen (another formulation of epoetin alfa), and Neorecormon.

135 a heavily glycosylated protein therapeutic (Epoetin Alfa).

136 fusion and recombinant human erythropoietin (epoetin alfa).

137 eable with recombinant human erythropoietin (epoetin alfa).

138 worth further exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative biologic expla

139 t between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI,

140 enter, placebo-controlled, clinical trial of epoetin alfa, 40,000 U subcutaneously, once weekly vs. m

141 anemic critically ill patients treated with epoetin alfa, all dosing regimens were well tolerated an

142 Epoetin alfa, compared with placebo, significantly decre

143 roxadustat and 0.68 (0.60 to 0.76) g/dl with epoetin alfa, demonstrating noninferiority (least square

144 S. liquefaciens was isolated from pooled epoetin alfa, empty vials of epoetin alfa that had been

145 raged over weeks 28-52 for roxadustat versus epoetin alfa, regardless of rescue therapy use, tested f

146 .6% with roxadustat and 84.5% and 57.5% with epoetin alfa, respectively.

147 ients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by baseline red blood cell tran

148 ety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke

149 ical improvement with luspatercept than with epoetin alfa, with benefits observed across patient subg

150 which placebo patients were crossed over to epoetin alfa.

151 bel phase during which all patients received epoetin alfa.

152 23 to 28% of these patients were prescribed epoetin alfa.

153 ed hazards ratio of 1.309 (P =.052) favoring epoetin alfa.

154 948 to 3831 during treatment with GM-CSF +/- epoetin alfa.

155 o define the optimal doses and schedules for epoetin alfa.

156 : 182 (50%) to luspatercept and 181 (50%) to epoetin alfa.

157 ith DD-CKD, with an AE profile comparable to epoetin alfa.

158 Hb levels increased from baseline with epoetin alfa.

159 nt is somewhat greater with continued weekly epoetin alfa.

160 a mouse model, single-dose CNTO 530 (unlike epoetin-alfa or darbepoietin-alfa) bolstered red cell pr

161 erythroblasts at frequencies multifold above epoetin-alfa or darbepoietin-alfa.

162 quently can be treated via administration of epoetin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-

163 AKT activation were similar for CNTO 530 and epoetin-alfa.

164 the present study to determine if utilizing epoetin alpha (EPO) with or without a higher dose of RVN

165 ilities with fixed characteristics including epoetin alpha dosing.

166 a patient who was treated with fixed-dosage epoetin alpha in the poorest versus best performing unit

167 All three are epoetin alpha products, reputed to have similar glycosyl

168 owth factor injections (darbepoetin alpha or epoetin alpha) during combination therapy with standard

169 01 continues to support a positive effect of epoetin-alpha therapy on the quality of life of patients

170 Recombinant human erythropoietin (epoetin-alpha), an effective alternative to blood transf

171 ents and trials of longer-acting versions of epoetin-alpha, such as the novel erythropoiesis-stimulat

172 ogists and anemia managers adjusted doses of epoetin and intravenous iron as clinically indicated.

173 s individualized and specific application of epoetin and iron for each patient, and significant cost

174 erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylas

175 anel found good evidence to recommend use of epoetin as a treatment option for patients with chemothe

176 anel found good evidence to recommend use of epoetin as a treatment option for patients with chemothe

177 hronic kidney disease patients who developed epoetin-associated PRCA and had 3 months or more follow-

178 Among chronic kidney disease patients with epoetin-associated PRCA, epoetin discontinuation and imm

179 We obtained reports of epoetin-associated pure red-cell aplasia from the Food a

180 en January 1998 and April 2004, 175 cases of epoetin-associated pure red-cell aplasia were reported f

181 isk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial.

182 d to intravenous methoxy polyethylene glycol-epoetin beta every 2 weeks (-0.71 g/L, 95% CI -2.20 to 0

183 igned to receive methoxy polyethylene glycol-epoetin beta every 2 weeks, and 224 to receive it every

184 ing intervals of methoxy polyethylene glycol-epoetin beta with standard epoetin treatment.

185 o had received Neorecormon (a formulation of epoetin beta); both are products that are marketed outsi

186 effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week in

187 l trial to lenalidomide or lenalidomide plus epoetin beta.

188 [SD, 9] vs. 18 weeks [SD, 7]; P = 0.004) of epoetin-beta than patients receiving monotherapy.

189 controlled trial investigated the effect of epoetin-beta to normalize hemoglobin values (13.0-15.0 g

190 etin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-beta.

191 In the absence of response, continuing epoetin beyond 6 to 8 weeks does not appear to be benefi

192 In the absence of response, continuing epoetin beyond 6-8 weeks does not appear to be beneficia

193 s likely to confer a clinical advantage over Epoetin by allowing less frequent dosing in patients tre

194 hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target

195 Iron overload before the availability of epoetin constituted a serious problem; our review of the

196 sease patients with epoetin-associated PRCA, epoetin discontinuation and immunosuppressive therapy or

197 erritin 500 to 1200 ng/ml, TSAT <or=25%, and epoetin dosage >or=225 IU/kg per wk or >or=22,500 IU/wk.

198 to investigate how ferric gluconate impacted epoetin dosage after DRIVE.

199 anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml an

200 Weekly mean epoetin dose administered in December 2004 and the adjus

201 ession models were used to estimate the mean epoetin dose and dose adjustment by profit, chain, and a

202 27 +/- 18,021 IU/wk, P = 0.003), whereas the epoetin dose essentially did not change for patients in

203 The initial dose was based on the average epoetin dose given during the week before the switch.

204 There was no significant change in epoetin dose over 6 months in the ergocalciferol or plac

205 Epoetin dose requirements for the study group decreased

206 facilities, for-profit facilities increased epoetin doses 3-fold for patients with hematocrit levels

207 ialysis patients who were receiving adequate epoetin doses and who had ferritin levels between 500 an

208 conate maintains hemoglobin and allows lower epoetin doses in anemic hemodialysis patients with low T

209 d ownership are associated with variation in epoetin dosing in the United States.

210 ich a patient receives dialysis might affect epoetin dosing patterns and has implications for future

211 Different epoetin dosing patterns suggest that large for-profit ch

212 bcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less

213 n restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(

214 ess erythropoietin-stimulating agent (median epoetin-equivalent units per week: 5306 units/wk ferric

215 available for at least 3 years (bevacizumab, epoetin, filgrastim, infliximab, pegfilgrastim, rituxima

216 randomized controlled trial supports use of epoetin for patients with anemia associated with low-ris

217 Use of epoetin for patients with less severe anemia (hemoglobin

218 Use of epoetin for patients with less severe anemia (Hgb level

219 units of RBCs compared with 127 units in the epoetin group (P < .0001).

220 n in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with a

221 m EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin levels (mean between-g

222 d clinical practice guideline for the use of epoetin in patients with cancer.

223 levels in renal anemia that is treated with epoetins is often incomplete and subject to much variati

224 ed that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intr

225 iency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.

226 ts from the Food and Drug Administration and epoetin manufacturers were reviewed for information on c

227 esatide once monthly or continued to receive epoetin one to three times a week, with the doses adjust

228 ing patterns and has implications for future epoetin policies.

229 imilar patient case-mix, the average dose of epoetin ranged from 17,832 U/wk at chain 5 (nonprofit fa

230 nsistently administered the highest doses of epoetin regardless of anemia status.

231 ibution of iron deficiency toward anemia and epoetin resistance among end-stage renal disease (ESRD)

232 times more likely to receive filgrastim and epoetin, respectively, after controlling for other facto

233 The highest rates of epoetin responsiveness were observed among persons whose

234 the patients, immunosuppressive treatments, epoetin responsiveness, and hematologic recovery.

235 poetin after the onset of PRCA, 56% regained epoetin responsiveness.

236 ronic kidney disease developed antibodies to epoetin, resulting in pure red cell aplasia (PRCA).

237 Epoetin should be titrated once the hemoglobin concentra

238 t, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percen

239 gluconate group required significantly less epoetin than their DRIVE dose (mean change of -7527 +/-

240 target range, with an average weekly dose of epoetin that is lower than with intravenous administrati

241 Reinitiation of epoetin therapy among individuals could be considered if

242 Recombinant epoetin therapy and correction of the chronic anemia of

243 Epoetin therapy for dialysis-related anemia is the singl

244 overshooting target hemoglobin levels under epoetin therapy may be a source of concern.

245 ho were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or

246 ialysis, despite concomitant erythropoietin (epoetin) therapy.

247 ical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg tiw) for a minimum of 4

248 ical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg) for a minimum of 4 week

249 were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 perce

250 Conventional treatment with epoetin to manage anaemia in chronic kidney disease need

251 re receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not r

252 = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).

253 ared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).

254 From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease deve

255 incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), r

256 venously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemog

257 stimulating agent is as safe as conventional epoetin treatment, and can maintain anaemia management i

258 lyethylene glycol-epoetin beta with standard epoetin treatment.

259 ts of supplementation with ergocalciferol on epoetin utilization and other secondary outcomes in pati

260 ficiency or deficiency, but had no effect on epoetin utilization or secondary biochemical and clinica

261 hropoietin antibodies were undetectable when epoetin was administered (89%).

262 At randomization, epoetin was increased 25% in both groups; further dosage

263 zed, controlled clinical trial comparing two epoetins were examined by the techniques of functional d

264 nalogue of recombinant human erythropoietin (Epoetin) which has an increased terminal half-life in an